401. Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease.
作者: Ilse Molendijk.;Bert A Bonsing.;Helene Roelofs.;Koen C M J Peeters.;Martin N J M Wasser.;Gerard Dijkstra.;C Janneke van der Woude.;Marjolijn Duijvestein.;Roeland A Veenendaal.;Jaap-Jan Zwaginga.;Hein W Verspaget.;Willem E Fibbe.;Andrea E van der Meulen-de Jong.;Daniel W Hommes.
来源: Gastroenterology. 2015年149卷4期918-27.e6页
Patients with perianal fistulizing Crohn's disease have a poor prognosis because these lesions do not heal well. We evaluated the effects of local administration of bone marrow-derived mesenchymal stromal cells (MSCs) to these patients from healthy donors in a double-blind, placebo-controlled study.
402. Pentoxifylline Treatment in Severe Acute Pancreatitis: A Pilot, Double-Blind, Placebo-Controlled, Randomized Trial.
作者: Santhi Swaroop Vege.;Tegpal Atwal.;Yan Bi.;Suresh T Chari.;Magdalen A Clemens.;Felicity T Enders.
来源: Gastroenterology. 2015年149卷2期318-20.e3页
In acute pancreatitis (AP) tumor necrosis factor-α mediates multi-organ failure; in animal models its blockade with pentoxifylline ameliorates AP. The efficacy of pentoxifylline in predicted severe AP (pSAP) was tested in a double-blinded, randomized, control trial. Twenty-eight patients with pSAP were randomized within 72 hours of diagnosis to pentoxifylline or placebo. Baseline characteristics were similar in both groups. The pentoxifylline group had fewer intensive care unit admissions and shorter intensive care unit and hospital stays of longer than 4 days (all P < .05). Patients receiving pentoxifylline had no adverse effects. Pentoxifylline within 72 hours of pSAP is safe; a larger study of pentoxifylline in AP is needed to confirm efficacy. ClinicalTrials.gov number: NCT01292005.
403. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
作者: Marieke J H Coenen.;Dirk J de Jong.;Corine J van Marrewijk.;Luc J J Derijks.;Sita H Vermeulen.;Dennis R Wong.;Olaf H Klungel.;Andre L M Verbeek.;Piet M Hooymans.;Wilbert H M Peters.;Rene H M te Morsche.;William G Newman.;Hans Scheffer.;Henk-Jan Guchelaar.;Barbara Franke.; .
来源: Gastroenterology. 2015年149卷4期907-17.e7页
More than 20% of patients with inflammatory bowel disease (IBD) discontinue thiopurine therapy because of severe adverse drug reactions (ADRs); leukopenia is one of the most serious ADRs. Variants in the gene encoding thiopurine S-methyltransferase (TPMT) alter its enzymatic activity, resulting in higher levels of thiopurine metabolites, which can cause leukopenia. We performed a prospective study to determine whether genotype analysis of TPMT before thiopurine treatment, and dose selection based on the results, affects the outcomes of patients with IBD.
404. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy.
作者: Tilman Sauerbruch.;Martin Mengel.;Matthias Dollinger.;Alexander Zipprich.;Martin Rössle.;Elisabeth Panther.;Reiner Wiest.;Karel Caca.;Albrecht Hoffmeister.;Holger Lutz.;Rüdiger Schoo.;Henning Lorenzen.;Jonel Trebicka.;Beate Appenrodt.;Michael Schepke.;Rolf Fimmers.; .
来源: Gastroenterology. 2015年149卷3期660-8.e1页
Patients with cirrhosis and variceal hemorrhage have a high risk of rebleeding. We performed a prospective randomized trial to compare the prevention of rebleeding in patients given a small-diameter covered stent vs those given hepatic venous pressure gradient (HVPG)-based medical therapy prophylaxis.
405. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
作者: Michael Charlton.;Gregory T Everson.;Steven L Flamm.;Princy Kumar.;Charles Landis.;Robert S Brown.;Michael W Fried.;Norah A Terrault.;Jacqueline G O'Leary.;Hugo E Vargas.;Alexander Kuo.;Eugene Schiff.;Mark S Sulkowski.;Richard Gilroy.;Kymberly D Watt.;Kimberly Brown.;Paul Kwo.;Surakit Pungpapong.;Kevin M Korenblat.;Andrew J Muir.;Lewis Teperman.;Robert J Fontana.;Jill Denning.;Sarah Arterburn.;Hadas Dvory-Sobol.;Theo Brandt-Sarif.;Phillip S Pang.;John G McHutchison.;K Rajender Reddy.;Nezam Afdhal.; .
来源: Gastroenterology. 2015年149卷3期649-59页
There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease.
406. Cognitive-behavioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with inflammatory bowel disease: a pilot randomised controlled trial.
作者: Antonina Mikocka-Walus.;Peter Bampton.;David Hetzel.;Patrick Hughes.;Adrian Esterman.;Jane M Andrews.
来源: BMC Gastroenterol. 2015年15卷54页
Studies have demonstrated usefulness of cognitive-behavioural therapy (CBT) in managing distress in inflammatory bowel disease (IBD); however, few have focused on IBD course. The present trial aimed to investigate whether adding CBT to standard treatment prolongs remission in IBD in comparison to standard therapy alone.
407. Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study.
作者: Nicholas J Talley.;G Richard Locke.;Yuri A Saito.;Ann E Almazar.;Ernest P Bouras.;Colin W Howden.;Brian E Lacy.;John K DiBaise.;Charlene M Prather.;Bincy P Abraham.;Hashem B El-Serag.;Paul Moayyedi.;Linda M Herrick.;Lawrence A Szarka.;Michael Camilleri.;Frank A Hamilton.;Cathy D Schleck.;Katherine E Tilkes.;Alan R Zinsmeister.
来源: Gastroenterology. 2015年149卷2期340-9.e2页
Antidepressants are frequently prescribed to treat functional dyspepsia (FD), a common disorder characterized by upper abdominal symptoms, including discomfort or postprandial fullness. However, there is little evidence of the efficacy of these drugs in patients with FD. We performed a randomized, double-blind, placebo-controlled trial to evaluate the effects of antidepressant therapy on symptoms, gastric emptying (GE), and meal-induced satiety in patients with FD.
408. Use of pethidine for percutaneous liver biopsy - a randomised, placebo-controlled, double blind study.
作者: Antony Pan.;Mohammed Alansari.;Ralf Lubcke.;Martin Schlup.;Merrilee Williams.;Margaret Fraser.;Sarah Buckingham.;Michael Schultz.
来源: BMC Gastroenterol. 2015年15卷33页
Percutaneous liver biopsy (PLB) is the "gold standard" in the diagnosis of liver diseases. A pilot trial has shown pethidine may reduce anxiety and the need for post-procedural pain relief. The aim of this study was to investigate the role of pre-procedural pethidine.
409. Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial.
作者: Jimme K Wiggers.;Robert J S Coelen.;Erik A J Rauws.;Otto M van Delden.;Casper H J van Eijck.;Jeroen de Jonge.;Robert J Porte.;Carlijn I Buis.;Cornelis H C Dejong.;I Quintus Molenaar.;Marc G H Besselink.;Olivier R C Busch.;Marcel G W Dijkgraaf.;Thomas M van Gulik.
来源: BMC Gastroenterol. 2015年15卷20页
Liver surgery in perihilar cholangiocarcinoma (PHC) is associated with high postoperative morbidity because the tumor typically causes biliary obstruction. Preoperative biliary drainage is used to create a safer environment prior to liver surgery, but biliary drainage may be harmful when severe drainage-related complications deteriorate the patients' condition or increase the risk of postoperative morbidity. Biliary drainage can cause cholangitis/cholecystitis, pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehydration. Two methods of preoperative biliary drainage are mostly applied: endoscopic biliary drainage, which is currently used in most regional centers before referring patients for surgical treatment, and percutaneous transhepatic biliary drainage. Both methods are associated with severe drainage-related complications, but two small retrospective series found a lower incidence in the number of preoperative complications after percutaneous drainage compared to endoscopic drainage (18-25% versus 38-60%, respectively). The present study randomizes patients with potentially resectable PHC and biliary obstruction between preoperative endoscopic or percutaneous transhepatic biliary drainage.
410. Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: a double-center and double-blind randomized clinical trial.
作者: Zhihua Liu.;Chao Li.;Meijin Huang.;Chao Tong.;Xingwei Zhang.;Lei Wang.;Hui Peng.;Ping Lan.;Peng Zhang.;Nanqi Huang.;Junsheng Peng.;Xiaojian Wu.;Yanxing Luo.;Huanlong Qin.;Liang Kang.;Jianping Wang.
来源: BMC Gastroenterol. 2015年15卷34页
Colorectal liver metastases (CLM) occur frequently and postoperative intestinal infection is a common complication. Our previous study showed that probiotics could decrease the rate of infectious complications after colectomy for colorectal cancer. To determine the effects of the perioperative administration of probiotics on serum zonulin levels which is a marker of intestinal permeability and the subsequent impact on postoperative infectious complications in patients with CLM.
411. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial.
作者: Paul Moayyedi.;Michael G Surette.;Peter T Kim.;Josie Libertucci.;Melanie Wolfe.;Catherine Onischi.;David Armstrong.;John K Marshall.;Zain Kassam.;Walter Reinisch.;Christine H Lee.
来源: Gastroenterology. 2015年149卷1期102-109.e6页
Ulcerative colitis (UC) is difficult to treat, and standard therapy does not always induce remission. Fecal microbiota transplantation (FMT) is an alternative approach that induced remission in small series of patients with active UC. We investigated its safety and efficacy in a placebo-controlled randomized trial.
412. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis.
作者: Noortje G Rossen.;Susana Fuentes.;Mirjam J van der Spek.;Jan G Tijssen.;Jorn H A Hartman.;Ann Duflou.;Mark Löwenberg.;Gijs R van den Brink.;Elisabeth M H Mathus-Vliegen.;Willem M de Vos.;Erwin G Zoetendal.;Geert R D'Haens.;Cyriel Y Ponsioen.
来源: Gastroenterology. 2015年149卷1期110-118.e4页
Several case series have reported the effects of fecal microbiota transplantation (FMT) for ulcerative colitis (UC). We assessed the efficacy and safety of FMT for patients with UC in a double-blind randomized trial.
413. Identification of Extracolonic Pathologies by Computed Tomographic Colonography in Colorectal Cancer Symptomatic Patients.
作者: Steve Halligan.;Katherine Wooldrage.;Edward Dadswell.;Urvi Shah.;Ines Kralj-Hans.;Christian von Wagner.;Omar Faiz.;Julian Teare.;Rob Edwards.;Clive Kay.;Guiqing Yao.;Richard J Lilford.;Dion Morton.;Jane Wardle.;Wendy Atkin.; .
来源: Gastroenterology. 2015年149卷1期89-101.e5页
Symptoms suggestive of colorectal cancer may originate outside the colorectum. Computed tomographic colonography (CTC) is used to examine the colorectum and abdominopelvic organs simultaneously. We performed a prospective randomized controlled trial to quantify the frequency, nature, and consequences of extracolonic findings.
414. Cost Efficacy of Metal Stents for Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial.
作者: Daisy Walter.;Petra G A van Boeckel.;Marcel J Groenen.;Bas L A M Weusten.;Ben J Witteman.;Gi Tan.;Menno A Brink.;Jan Nicolai.;Adriaan C Tan.;Joyce Alderliesten.;Niels G Venneman.;Wim Laleman.;Jeroen M Jansen.;Alexander Bodelier.;Frank L Wolters.;Laurens A van der Waaij.;Ronald Breumelhof.;Frank T M Peters.;Robbert C H Scheffer.;Max Leenders.;Meike M C Hirdes.;Ewout W Steyerberg.;Frank P Vleggaar.;Peter D Siersema.
来源: Gastroenterology. 2015年149卷1期130-8页
Endoscopic stents are placed for palliation of extrahepatic bile duct obstruction. Although self-expandable metal stents (SEMS) remain patent longer than plastic stents, they are more expensive. We aimed to evaluate which type of stent (plastic, uncovered SEMS [uSEMS], or partially covered SEMS [pcSEMS]) is the most effective and we assessed costs.
415. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis.
作者: Chandan Kumar Kedarisetty.;Lovkesh Anand.;Ankit Bhardwaj.;Ajeet Singh Bhadoria.;Guresh Kumar.;Ashish Kumar Vyas.;Paul David.;Nirupama Trehanpati.;Archana Rastogi.;Chhagan Bihari.;Rakhi Maiwall.;Hitendra Kumar Garg.;Chitranshu Vashishtha.;Manoj Kumar.;Vikram Bhatia.;Shiv Kumar Sarin.
来源: Gastroenterology. 2015年148卷7期1362-70.e7页
Patients with decompensated cirrhosis have significantly reduced survival without liver transplantation. Granulocyte colony-stimulating factor (G-CSF) has been shown to increase survival in patients with acute-on-chronic liver failure, and erythropoietin promoted hepatic regeneration in animal studies. We performed a double-blind, randomized, placebo-controlled trial to determine whether co-administration of these growth factors improved outcomes for patients with advanced cirrhosis.
416. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
作者: Joon Hyeok Lee.;Jeong-Hoon Lee.;Young-Suk Lim.;Jong Eun Yeon.;Tae-Jin Song.;Su Jong Yu.;Geum-Youn Gwak.;Kang Mo Kim.;Yoon Jun Kim.;Jae Won Lee.;Jung-Hwan Yoon.
来源: Gastroenterology. 2015年148卷7期1383-91.e6页
No adjuvant therapy has been shown to extend the survival of patients with hepatocellular carcinoma (HCC) receiving curative treatment. We investigated whether injections of activated cytokine-induced killer (CIK) cells (CD3+/CD56+ and CD3+/CD56- T cells and CD3-/CD56+ natural killer cells) prolongs recurrence-free survival of patients after curative therapy for HCC.
417. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
作者: Niels Vande Casteele.;Marc Ferrante.;Gert Van Assche.;Vera Ballet.;Griet Compernolle.;Kristel Van Steen.;Steven Simoens.;Paul Rutgeerts.;Ann Gils.;Séverine Vermeire.
来源: Gastroenterology. 2015年148卷7期1320-9.e3页
Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine whether dosing based on therapeutic drug monitoring increases rate of remission and whether continued concentration-based dosing is superior to clinically based dosing of infliximab for maintaining remission in patients with CD and UC.
418. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
作者: Daniel A Leffler.;Ciaran P Kelly.;Peter H R Green.;Richard N Fedorak.;Anthony DiMarino.;Wendy Perrow.;Henrik Rasmussen.;Chao Wang.;Premysl Bercik.;Natalie M Bachir.;Joseph A Murray.
来源: Gastroenterology. 2015年148卷7期1311-9.e6页
Celiac disease (CeD) is a prevalent autoimmune condition. Recurrent signs and symptoms are common despite treatment with a gluten-free diet (GFD), yet no approved or proven nondietary treatment is available.
419. Cap assisted colonoscopy for the detection of serrated polyps: a post-hoc analysis.
作者: Fadi Rzouq.;Neil Gupta.;Sachin Wani.;Prateek Sharma.;Ajay Bansal.;Amit Rastogi.
来源: BMC Gastroenterol. 2015年15卷11页
Colonoscopy offers limited protection against right-sided colon cancer, a significant proportion of which arise from the serrated pathway of carcinogenesis. The aim of this study was to compare cap-assisted colonoscopy and standard high-definition white light colonoscopy regarding serrated polyps' detection.
420. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
作者: Julián Panés.;Chinyu Su.;Andrew G Bushmakin.;Joseph C Cappelleri.;Carla Mamolo.;Paul Healey.
来源: BMC Gastroenterol. 2015年15卷14页
Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC). The objective of the current study was to determine the effect of tofacitinib on patient-reported outcomes (PROs).
|